COLL, US19459J1043

Collegium Pharmaceutical stock has a November 5 earnings date

Published on 10/15/2026 at 21:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The price-to-earnings ratio stood at 18.79 on October 15, 2026. Collegium Pharmaceutical stock costs EUR 20.70 on October 15, 2026 at 9:42 p.m. CEST, up 3.51 percent versus the Nasdaq prior close.

Earnings and valuation

The next earnings report is scheduled for November 5, 2026, before the market opens.
The price-to-earnings ratio was 18.79 on October 15, 2026.
Collegium Pharmaceutical stock costs EUR 20.70 at Lang & Schwarz on October 15, 2026 at 9:42 p.m. CEST, 3.51 percent above the Nasdaq prior close of October 14, 2026.
Market capitalization stood at USD 758.5 million on October 15, 2026.

COLL, US19459J1043, Illustration mit AI erstellt.

Collegium Pharmaceutical stock has a November 5 earnings date, with the report estimated before the market opens by MarketBeat. The company was trading at EUR 20.70 at Lang & Schwarz on October 15, 2026 at 9:42 p.m. CEST, 3.51 percent above the Nasdaq prior close of October 14, 2026.

Valuation has a clear number

Collegium's price-to-earnings ratio stood at 18.79 on October 15, 2026. Market capitalization was USD 758.5 million on the same date, while trading volume reached 618,693 shares against an average of 763,828.

The company operates in specialty pharmaceuticals, with products spanning pain management and neuropsychiatry. Its investor-relations profile describes a portfolio that includes treatments for serious and persistent pain and medicine for attention-deficit hyperactivity disorder, according to Collegium Pharmaceutical.

Price position after the move

On Nasdaq, the stock was last quoted at USD 23.30 on October 15, 2026 at 3:50 p.m. ET, up 3.51 percent from USD 22.51. The same quote placed the shares 8.72 percent above the 52-week low of USD 21.43 and 54.12 percent below the 52-week high of USD 50.79.

The euro quotation therefore sits well below the stock's annual dollar high, while the daily Nasdaq move was stronger than the 2.35 percent gain at Amneal Pharmaceuticals. The price position is also different from Supernus Pharmaceuticals, which fell 1.84 percent on October 15, 2026.

Comparison with peers

COLL (Nasdaq, USD): plus 3.51 percent, P/E 18.79, market capitalization USD 758.5 million.

Supernus Pharmaceuticals (Nasdaq, USD): minus 1.84 percent, P/E minus 20.53, market capitalization USD 2.3 billion.

Amneal Pharmaceuticals (Nasdaq, USD): plus 2.35 percent, P/E 39.72, market capitalization USD 6.2 billion.

Dates and valuation

The next scheduled event is the estimated third-quarter 2026 report on November 5, 2026, before the market opens. Collegium's second-quarter 2026 revenue was USD 199.88 million and operating cash flow was USD 71.32 million, providing the latest reported operating context.

Closing level in euros

For investors in Germany, the key distinction is the currency of the quotation: the Lang & Schwarz level is EUR 20.70, while the primary Nasdaq quote is in USD. The daily Nasdaq move and the euro price point in the same direction on October 15, 2026.

Collegium Pharmaceutical stock was trading at EUR 20.70 at Lang & Schwarz on October 15, 2026 at 9:42 p.m. CEST, 3.51 percent above the Nasdaq prior close of October 14, 2026 (USD 22.51). The further course of trading is shown by the continuously updated real-time quote of Collegium Pharmaceutical stock.